Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-12-01T05:05:48.699Z Has data issue: false hasContentIssue false

Study of the contributory factors to metabolic abnormalities in resistant schizophrenia

Published online by Cambridge University Press:  23 March 2020

S. Ramos Perdigues*
Affiliation:
Nuestra Señora de Jesus, SpainNuestra Señora de Jesus, Spain
A. Mane Santacana
Affiliation:
Hospital del Mar, Psychiatry, Barcelona, Spain
P. Salgado Serrano
Affiliation:
Hospital del Mar, Psychiatry, Barcelona, Spain
E. Jove Badia
Affiliation:
Centre Dr. Emili Mira, Psychiatry, Santa Coloma de Gramanet, Spain
X. Valiente Torrelles
Affiliation:
Centre Dr. Emili Mira, Psychiatry, Santa Coloma de Gramanet, Spain
L. Ortiz Sanz
Affiliation:
Centre Dr. Emili Mira, Psychiatry, Santa Coloma de Gramanet, Spain
J.R. Fortuny Olive
Affiliation:
Centre Dr. Emili Mira, Psychiatry, Santa Coloma de Gramanet, Spain
V. Perez Sola
Affiliation:
Hospital del Mar, Psychiatry, Barcelona, Spain
F. Dinamarca
Affiliation:
Centre Dr. Emili Mira, Psychiatry, Santa Coloma de Gramanet, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Schizophrenia is a developmental disorder that includes non-psychiatric abnormalities [2]. Metabolic abnormalities prior to antipsychotic treatment exist. The clozapine metabolic profile causes clozapine underuse in resistant schizophrenia [1].

Objectives

To correlate metabolic profile with psychiatric severity and compare the correlations between clozapine/non-clozapine patients.

Aims

To determine possible contributory factors to metabolic abnormalities in schizophrenia.

Methods

We cross-sectionally analyzed all patients from a Spanish long-term mental care facility (n = 139). Schizophrenic/schizoaffective patients were selected (n = 118). N = 31 used clozapine. We paired clozapine and non-clozapine patients by sex and age and assessed metabolic and psychopathologic variables.

We compared psychopathologic variables between patients with/without cardiometabolic treatment and the differences between clozapine/non-clozapine groups.

Results

We analyzed: 27 clozapine/29 non-clozapine patients. A total of 67,9% males with a mean age of 51.3 (SD 9.6) years. In the whole sample TG negatively correlated with Negative-CGI (r: −0,470, P: 0.049) and HDL-cholesterol correlates with Global-CGI(r: 0,505, P: 0.046). Prolactin correlated with the number of antipsychotics (r: 0.581, P: 0.023) and IMC (r: 0.575, P: 0.025). Clozapine group took less antipsychotics [Fisher (P: 0.045)] and had higher scores in total BRPS scale [t-Student (P: 0.036)]. They did not use more cardiometabolic treatment. There were no psychopathological differences between cardiometabolic treated/non-treated patients. In the non-cardiometabolic treated group (n = 35/62,5%), IMC negatively correlated with positive and total BPRS, positive, cognitive and global-CGI. We found negative correlations between metabolic parameters and psychopathology in clozapine (40%) and non-clozapine subgroups (60%). In the cardiometabolic treated group (n = 21/37,5%), we did not find these correlations in either of clozapine (61.9%) or non-clozapine (38.1%) subgroups.

Conclusions

Severity [2], prolactine [3] and treatment [1] could play a role in metabolic parameters. In our sample we found negative correlations between psychopathological and metabolic parameters.

References not available.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV1184
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.